CJC-1295 with Ipamorelin: A Targeted Growth Hormone Pulse.

Why Two Peptides Instead of One.

Growth hormone release from the pituitary is governed by two complementary signals. GHRH (growth hormone releasing hormone) stimulates the GHRH receptor, prompting the pituitary to produce and release GH. Ghrelin and ghrelin-mimetics stimulate a different receptor — the growth hormone secretagogue receptor (GHS-R) — which amplifies the same GH pulse. Combining a GHRH analog with a GHRP produces a stronger, more pronounced pulsatile release than either signal alone.

The CJC-1295/Ipamorelin combination uses this physiology deliberately:

• CJC-1295 is a GHRH analog modified with a Drug Affinity Complex (DAC) that extends its half-life relative to native GHRH. The DAC modification allows the molecule to bind albumin in circulation, prolonging its action and reducing the dosing frequency required.
• Ipamorelin is a synthetic pentapeptide selective for the GHS-R (ghrelin receptor). The key word is selective — older GHRPs like GHRP-2, GHRP-6, and hexarelin are non-selective and produce off-target elevation of cortisol, prolactin, and aldosterone. Ipamorelin avoids that.

The result, in patients with measurable GH-axis decline, is a more pronounced response than sermorelin alone — while preserving the body's pulsatile pattern and natural feedback, and without the cortisol/prolactin elevation that would itself produce side effects.

Who This Combination Is For.

The clinical profile is similar to sermorelin:

• Documented IGF-1 decline below age-adjusted reference, paired with a clear clinical pattern.
• Sleep quality decline — reduced restorative deep sleep, more nocturnal awakenings.
• Recovery and body composition deterioration despite consistent effort — lean mass losing ground to fat mass, slower training recovery.
• Energy and resilience decline across the day.

The choice between sermorelin alone and CJC-1295/Ipamorelin combination comes down to the magnitude of response a patient's biomarkers and clinical profile suggest is appropriate. Patients with more profound IGF-1 decline often see better response on the combination; patients with mild decline often do well on sermorelin alone. We do not prescribe either for cosmetic, performance, or "longevity" reasons without supporting biomarker data.

How It Fits in The CLARITY Methodology.

The combination is calibrated to the CLARITY 42-marker baseline. Critical adjacent factors that affect GH-axis function and that we evaluate before any peptide prescription:

• Thyroid function. Suppressed thyroid blunts GH response. We address thyroid first.
• Sex hormones. Low testosterone or estradiol blunts GH effects. Hormone optimization often comes first or runs in parallel.
• Sleep architecture. The majority of endogenous GH release happens during deep sleep. If sleep is broken, peptide stimulus has limited substrate to work with.
• Insulin sensitivity. Insulin resistance attenuates GH effects. We address this directly.

The protocol is not "give the peptide, wait for results." It is calibrate the upstream, layer the peptide, re-measure, adjust.

Monitoring — What We Track and Why.

IGF-1

The single most stable marker of GH-axis function. We target the upper-normal range for the patient's age — not supra-physiologic. Re-tested at 8-12 weeks and at each subsequent adjustment.

Fasting Glucose and HbA1c

GH has counter-regulatory effects on glucose metabolism — a meaningful consideration in any protocol that stimulates endogenous GH release. The combination's stronger response makes this monitoring more important than with sermorelin alone.

Clinical Response

Sleep quality, recovery, body composition, energy, and functional capacity. Patient-reported response combined with lab data informs every adjustment.